Tivozanib

Definition

An orally bioavailable inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2 and 3 with potential antiangiogenic and antineoplastic activities. Tivozanib binds to and inhibits VEGFRs 1, 2 and 3, which may result in the inhibition of endothelial cell migration and proliferation, inhibition of tumor angiogenesis and tumor cell death. VEGFR tyrosine kinases, frequently overexpressed by a variety of tumor cell types, play a key role in angiogenesis.

Also known as AV 951, AV-951, AV951, TIVOZANIB, Urea, N-[2-chloro-4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(5-methyl-3-isoxazolyl)- — per NCIT

Also identified as

• ATC L01EK03 per RXNORM
• NCIT NCIT:C85444 per NCIT
• SCTID 738747006 per RXNORM
• SCTID 763513002 per RXNORM
• UNII 172030934T per RXNORM

Indications